Kanishka Jayasundera
Retina Specialist · Ann Arbor, MINPI 1992090625
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $43,040 of the $49,329 with a category attached, or 87.2%. Johnson & Johnson accounts for 97.2% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $36,921 and has fallen 79.2% since, to $7,678 in 2025.
Across 51 payments — averaging $967.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$48K
- Biocryst Pharmaceuticals, Inc.$1K
- Alcon$123
Across 10 payments — averaging $7689.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cortigent Inc$29K
- Spark Therapeutics, Inc.$23K
- AbbVie$18K
- Astellas Pharma Global Development$8K
What the payments were for
- Consulting fees$43,04087%
- Travel & lodging$5,34011%
- Food & beverage$9502%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 49 | $47,942 |
| Biocryst Pharmaceuticals, Inc. | 1 | $1,265 |
| Alcon | 1 | $123 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,329 in reported general payments places this provider in the 85th percentile of 52 retina specialist providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NevanacNepafenac | 11 | $4,704 |
| Prednisolone Acetate | 18 | $1,111 |
| Brimonidine Tartrate | 11 | $728 |
| Dorzolamide Hcl | 35 | $704 |
| Ofloxacin | 34 | $353 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 17 | $321 |
| Ketorolac Tromethamine | 20 | $319 |
| Timolol Maleate | 13 | $229 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Ann Arbor
- Michael HuvardAnn Arbor$126
- Jeremy WolfeRoyal Oak$809K
- Lisa FaiaRoyal Oak$520K
- Tarek HassanRoyal Oak$460K
- Asheesh TewariDearborn$204K
- Sandeep RandhawaRoyal Oak$94K
- Kimberly DrenserRoyal Oak$79K
- Edward KorotGrand Rapids$44K
- Adam WeinerRoyal Oak$31K
- Michael TreseRoyal Oak$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.